Xencor Inc. XNCR

What this company does

Its approach to protein design includes engineering Fc domains, the parts of antibodies that interact with multiple segments of the immune system and control antibody structure, which can be substituted for natural Fc domains to provide features such as bispecific structure and extended half-life and serve as the scaffolds for its XmAb drug candidates. Three marketed medicines have been developed with its XmAb protein engineering technologies. As of December 31, 2025, it had 260 full-time employees, of which 212 were engaged in research and development activities and 48 were engaged in business development, information systems, facilities, human resources, or administrative support. Its principal offices are located at 465 North Halstead Street, Suite 200, Pasadena, California. Xencor was incorporated in California in August 1997 under the name Xencor, and reincorporated in the state of Delaware under the name Xencor, Inc. in September 2004.

Written from the business description in Xencor Inc's annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.